{"id":26249,"date":"2025-06-12T14:59:59","date_gmt":"2025-06-12T12:59:59","guid":{"rendered":"https:\/\/idibell.cat\/es\/?post_type=agenda&p=26249"},"modified":"2025-06-12T14:59:59","modified_gmt":"2025-06-12T12:59:59","slug":"idibellfellows-idibellfellows-jose-luis-rocamora-pau-fiolpau-fiol-jose-luis-rocamora","status":"publish","type":"agenda","link":"https:\/\/idibell.cat\/es\/agenda\/idibellfellows-idibellfellows-jose-luis-rocamora-pau-fiolpau-fiol-jose-luis-rocamora\/","title":{"rendered":"#IDIBELLfellows: Jose Luis Rocamora & Pau Fiol"},"content":{"rendered":"

ERK Signaling in Vascular Homeostasis: Therapeutic Implications for Hereditary Hemorrhagic Telangiectasia
\n<\/strong>\"\"Jose Luis Rocamora Navarro – Systemic, vascular diseases and ageing group
\n<\/strong>Hereditary Hemorrhagic Telangiectasia (HHT) is a rare disease characterized by vascular malformations. It is typically caused by mutations leading to ALK1 signaling haploinsufficiency during angiogenesis. This work demonstrates that ALK1 signaling downregulates ERK pathway, elucidating a new molecular mechanism in endothelial cells. Moreover, it reveals that HHT is associated to ERK signaling overactivation, proposing this pathway as a new therapeutical target for this disease with no curative treatment. In this line, in vivo experiments with clinically approved MEK inhibitors ameliorate HHT symptoms in mouse models.<\/em><\/p>\n

 <\/p>\n

Enhancing immune responses in cancer virotherapy: Oncolytic Adenoviruses Armed with a Bispecific T Cell Engager Targeting Folate Receptor Alpha for the Treatment of Ovarian Cancer<\/strong>
\n\"\"Pau Fiol Mata – Cancer immunotherapy group
\nOncolytic adenoviruses (OAds) replicate in tumor cells and trigger immune responses, but clinical efficacy is limited. Bispecific T cell engagers (BsTEs) redirect T cells to tumors but have short half-life and toxicity. Combining OAds with BsTEs enhances efficacy: infected cells undergo oncolysis and release BsTEs, activating T cells locally. This study engineered ICOVIR15K to express a BsTE targeting folate receptor alpha (FR\u03b1). Although replication was slightly reduced, it maintained strong oncolytic activity and activated T cells in vitro. In mice, ICOVIR15K-FR\u03b1BsTE plus human T cells delayed tumor growth, showing promise for cancer immunovirotherapy.<\/em><\/p>\n","protected":false},"featured_media":14895,"template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"tags":[402,392],"class_list":["post-26249","agenda","type-agenda","status-publish","has-post-thumbnail","hentry","tag-cancer","tag-translationalmedicine"],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/agenda\/26249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/agenda"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/agenda"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media\/14895"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=26249"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=26249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}